Skip to main content
Premium Trial:

Request an Annual Quote

Morphosys, GeneFrontier Expand HuCAL Deal to Include Antibody Development

NEW YORK (GenomeWeb News) — Morphosys today said it has expanded a 2-year-old marketing agreement with GeneFrontier to include HuCAL-based research, and the sales of any resulting antibody products.
 
The original agreement, signed in 2004, gave Tokyo-based GeneFrontier rights to market the Human Combinatorial Antibody Library technology in Japan for research and therapeutic applications.
 
Under the expanded deal, GeneFrontier will use the HuCAL Gold library to develop antibodies, and it has installed the technology in its Tokyo lab to conduct the research.
 
GeneFrontier paid Morphosys “a financial compensation” for access to the technology, Morphosys said. The companies also will share commercialization rights to antibodies discovered by GeneFrontier and its research partners.
 
Financial terms of the agreement were not released.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.